Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 82.50% is 13% above its 5-year average of 73.17%, near the high end of its 5-year range (40.39%–83.55%).
0.70% above its 12-month average of 81.93%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 82.06%.
GROSS MARGIN
82.50%
GROSS MARGIN AVG TTM
81.93%
GROSS MARGIN AVG 3Y
79.04%
GROSS MARGIN AVG 5Y
73.17%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.70%
CURRENT VS 3Y AVG
+4.38%
CURRENT VS 5Y AVG
+12.75%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.44%
median of 787 covered companies
CURRENT VS SECTOR MEDIAN
+104.01%
vs the sector median at left
Market Cap
$230.80M
Gross Margin
99.39%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
25.00%
Market Cap
$232.96M
Gross Margin
71.12%
TTM Avg
81.41%
3Y Avg
85.88%
5Y Avg
90.00%
Market Cap
$224.89M
Gross Margin
71.79%
TTM Avg
68.33%
3Y Avg
60.69%
5Y Avg
55.54%
Market Cap
$223.45M
Gross Margin
94.68%
TTM Avg
99.69%
3Y Avg
74.84%
5Y Avg
66.56%
Market Cap
$237.41M
Gross Margin
68.57%
TTM Avg
73.00%
3Y Avg
80.96%
5Y Avg
81.80%
Market Cap
$237.27M
Gross Margin
79.48%
TTM Avg
71.93%
3Y Avg
74.52%
5Y Avg
72.98%
Market Cap
$221.16M
Gross Margin
-31952.78%
TTM Avg
-15926.39%
3Y Avg
-7913.19%
5Y Avg
-5242.13%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Biodesix, Inc. (BDSX) | $230.37M | 82.50% | 81.93% | 79.04% | 73.17% |
| BioAge Labs Inc. (BIOA)vs › | $230.80M | 99.39% | 50.00% | 25.00% | 25.00% |
| MacroGenics, Inc. (MGNX)vs › | $232.96M | 71.12% | 81.41% | 85.88% | 90.00% |
| Profound Medical Corp. (PROF)vs › | $224.89M | 71.79% | 68.33% | 60.69% | 55.54% |
| Keros Therapeutics, Inc. (KROS)vs › | $223.45M | 94.68% | 99.69% | 74.84% | 66.56% |
| High Tide Inc. (HITI)vs › | $236.81M | 25.85% | 26.57% | 27.09% | 30.11% |
| SIGA Technologies, Inc. (SIGA)vs › | $237.41M | 68.57% | 73.00% | 80.96% | 81.80% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $237.27M | 79.48% | 71.93% | 74.52% | 72.98% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $221.16M | -31952.78% | -15926.39% | -7913.19% | -5242.13% |
| InflaRx N.V. (IFRX)vs › | $237.88M | -24677.94% | -13289.35% | -6830.59% | -4553.73% |
Gross Margin
82.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 82.06% |
| 2026-03-31 | 83.55% |
| 2025-12-31 | 83.03% |
| 2025-09-30 | 81.14% |
| 2025-06-30 | 79.86% |
| 2025-03-31 | 79.38% |
| 2024-12-31 | 78.75% |
| 2024-09-30 | 76.98% |
| 2024-06-30 | 78.37% |
| 2024-03-31 | 78.57% |
| 2023-12-31 | 77.00% |
| 2023-09-30 | 76.07% |
| 2023-06-30 | 72.73% |
| 2023-03-31 | 65.01% |
| 2022-12-31 | 65.59% |
| 2022-09-30 | 67.29% |
| 2022-06-30 | 63.65% |
| 2022-03-31 | 50.60% |
| 2021-12-31 | 65.49% |
| 2021-09-30 | 58.32% |
| 2021-06-30 | 40.39% |
| 2021-03-31 | 36.89% |
| 2020-12-31 | 45.79% |
| 2020-09-30 | 57.67% |
| 2020-06-30 | 55.79% |
| 2020-03-31 | 68.98% |
| 2019-12-31 | 77.87% |
| 2019-09-30 | 61.87% |
| 2019-06-30 | 77.79% |
| 2019-03-31 | 77.79% |
| 2018-06-30 | 78.44% |
| 2018-03-31 | 78.44% |
